secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxart, Inc. (VXRT)
CIK:        0000072444
Form:       8-K
Filed at:   2026-03-12T23:59:59+00:00
Accession:  0001437749-26-007968
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaxart reports FY2025 net income of $16.3M vs loss; revenue $237.3M; cash runway into Q2 2027
--------------------------------------------------------------------------------

- Net income $16.3M ($0.07 EPS) vs net loss $66.9M ($0.33 loss) in FY2024.
- Revenue $237.3M, up from $28.7M, driven by BARDA contract and Dynavax collaboration.
- Cash, equivalents & investments $63.8M; runway into Q2 2027.
- COVID-19 Phase 2b sentinel cohort data (400 subjects) expected early Q2 2026; main cohort topline Q4 2026.
- Published Phase 1 norovirus data shows passive antibody transfer to infants via breast milk; next trial dependent on partnership.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/72444/000143774926007968/0001437749-26-007968-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/72444/000143774926007968/vxrt20260311_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-007968

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer